Approach to the patient: Low testosterone concentrations in men with obesity

Simple item page
dc.contributor.authorMuir, C.A.
dc.contributor.authorWittert, G.A.
dc.contributor.authorHandelsman, D.J.
dc.date.issued2025
dc.descriptionOnlinePubl
dc.description.abstractPathologic hypogonadism occurs when serum testosterone is significantly and persistently reduced by irreversible organic (structural, genetic) disorders of the hypothalamic pituitary testicular axis. Men with pathologic hypogonadism require lifelong testosterone replacement. In contrast, mild or moderate reductions in serum testosterone frequently accompany obesity, and its numerous comorbidities in men are best considered nongonadal illness syndromes, wherein reduction in serum testosterone is usually reversible upon amelioration of the underlying nongonadal illness. Obesity can result in nonspecific symptoms in conjunction with reduced serum testosterone and serum SHBG. Obesity-related reductions in SHBG, testosterone's principal circulating carrier protein, are primarily responsible for measured reductions in testosterone. However, obesity is not a cause of pathological hypogonadism, and proportionately reduced testosterone and SHBG concentrations accompanied by normal serum LH and FSH concentrations confirm a eugonadal state, best described as the pseudo-hypogonadism of obesity. Herein we demonstrate how clinically significant weight loss substantially reverses obesity-related reductions in serum testosterone and ameliorates nonspecific symptoms resembling, but not due to, androgen deficiency. The important reversible steps include weight reduction and optimizing management of type 2 diabetes mellitus, obstructive sleep apnea, depression, and other obesity-related comorbidities as well as rationalizing concomitant drug regimens. In the absence of pathological hypogonadism, testosterone treatment is less effective than a diet and lifestyle intervention to rectify the reversible conditions responsible for the nonspecific symptoms and associated reduced serum testosterone concentrations observed in men with obesity. As such, testosterone treatment is not indicated, and unwarranted off-label testosterone treatment can lead to adverse effects such as infertility, elevated hematocrit requiring venesection, a prothrombotic state, and testosterone dependence.
dc.description.statementofresponsibilityChristopher A Muir, Gary A Wittert, David J Handelsman
dc.identifier.citationJournal of Clinical Endocrinology and Metabolism, 2025; dgaf137-1-dgaf137-6
dc.identifier.doi10.1210/clinem/dgaf137
dc.identifier.issn0021-972X
dc.identifier.issn1945-7197
dc.identifier.orcidWittert, G.A. [0000-0001-6818-6065]
dc.identifier.urihttps://hdl.handle.net/2440/146641
dc.language.isoen
dc.publisherOxford University Press
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/GNT1197361
dc.rights© The Author(s) 2025. Published by Oxford University Press on behalf of the Endocrine Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. See the journal About page for additional terms.
dc.source.urihttps://doi.org/10.1210/clinem/dgaf137
dc.subjectandrogen deficiency
dc.subjecthypogonadism
dc.subjecttestosterone
dc.subjectobesity
dc.titleApproach to the patient: Low testosterone concentrations in men with obesity
dc.typeJournal article
pubs.publication-statusPublished online

Files

Collections

Research Outputs